A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: DRUG: SI-B003
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: SystImmune Inc.